For J.K. Grant, participating in a test of a potential lung cancer vaccine is, as she puts it, her “civic duty.”

Grant was diagnosed with lung cancer last year, which resulted in surgery to remove tumors and parts of her right lung.

Shortly after, her physician asked if she would be willing to participate in a study testing whether a new vaccine is effective in preventing a recurrence of the most common type of lung cancer.

Grant didn’t hesitate. “No, not a bit,” said Grant, 65, of Everett. “It might help someone else.”

The vaccine is being tested at Providence Regional Cancer Partnership, one of 141 sites nationally and 400 sites across the world working on the study. A total of 2,270 patients are expected to participate.